NasdaqGM:CRVSBiotechs
Is Corvus Pharmaceuticals (CRVS) Still Attractive After A 185% Monthly Surge?
If you are wondering whether Corvus Pharmaceuticals at US$19.06 is still offering value after a strong run, the key question now is how that price stacks up against what the business might be worth.
The stock has been very volatile recently, with a 30 day return of 185.3%, a 1 year return of 253.6%, and a 3 year return that is well over 7x, even though the last 7 days saw a 9.0% decline.
That mix of sharp gains and a recent pullback often lines up with shifting expectations around the...